Clinical Trials

41 enrolled

Neoplasms, Plasma Cell

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

Phase 1 Active not recruiting

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

19 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06066359 2026-03-11

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

44 enrolled

Neoplasms, Plasma Cell

NCT03633955 2026-03-05

REALIZE

Phase 1 Recruiting

60 enrolled

Phase 1 Not yet recruiting

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT07297160 2026-03-04

CALySSEY

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT05745285 2026-02-20

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Phase NA Recruiting

400 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

40 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01269593 2026-01-15

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

63 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

14 enrolled 15 charts

Phase 2/3 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

300 enrolled

Other hematologic neoplasmPlasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00466674 2025-12-19

IFM 2005-03

Phase 2 Completed

13 enrolled

Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

30 enrolled

Neoplasms, Plasma Cell

NCT04268199 2025-12-15

EASE

Phase 2 Recruiting

100 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

49 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

14 enrolled

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT06947083 2025-12-03

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Phase 2 Recruiting

39 enrolled

Neoplasms, Plasma Cell

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

187 enrolled 14 charts 2 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02244125 2025-11-24

PCD

Phase 2 Completed

100 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

4 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01526096 2025-11-05

Stem Cell Transplantation for Patients With Multiple Myeloma

30 enrolled

Neoplasms, Plasma Cell

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Phase 1/2 Recruiting

30 enrolled

Phase 1 Active not recruiting

Neoplasms, Plasma Cell

NCT00881920 2025-10-21

CHARKALL

54 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Phase 2/3 Recruiting

900 enrolled

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Phase 2/3 Recruiting

900 enrolled

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Phase 2/3 Recruiting

900 enrolled